Abstract Views :442 |
PDF Views:0
Authors
Affiliations
1 Department of Pharmaceutics, Adhiparasakthi College of Pharmacy, Melmaruvathur 603319.Tamilnadu, IN
2 Department of Pharmaceutics, School of Pharmacy, Surya Group of Institutions, Vikravandi, Villupuram Dist.605 652. Tamilnadu, IN
3 Department of Pharmaceutical Analysis, Adhiparasakthi College of Pharmacy, Melmaruvathur-603319.Tamilnadu, IN
Source
Asian Journal of Research in Pharmaceutical Sciences, Vol 7, No 4 (2017), Pagination: 222-226
Abstract
The present investigation attempted to study the effect of disintegrants and processing methods on the physicochemical and in vitro release characteristics of immediate release tablets of Bosentan Monohydrate. To achieve this goal various formulations of Bosentan Monohydrate were prepared by direct compression, wet granulation and fluidized bed granulation methods to achieve maximum drug content with reference to innovator. Varying proportion of disintegrants such as sodium starch glycolate, pregelatinised starch used to compare drug release profile with innovator. Different formulations were prepared and evaluated with respect to various precompression and post compression parameters. The results indicated that the superdisintegrants used have influenced on the disintegration time. The final selection of the formulation F8 (f2 = 71) containing sodium starch glycolate was based on highest f2 value among all formulations with reference to marketed product.
Keywords
Bosentan Monohydrate, Direct Compression, Wet Granulation, Fluid Bed Granulation, Disintegrants, Drug Release.
References
- Abhay Gupta, Robert L. Hunt, Rakhi B Shah, Vilayat A Sayeed, Mansoor A Khan. AAPS Pharm SciTech 2009; 10(2):495-499.
- Rai VK, Pathak N, Bhaskar R, Nandi BC, Dey S, Tyagi LK. Int J Pharm Sci Drug Res 2009; 1(1):51-54.
- Shiyani BG, Dholakiya RB, Akbari BV, Lodhiya DJ, Ramani Jk. J Pharm Res 2009;2(9):1460-1464.
- Smith B, Walter K, Dycus E, Hubert M, Birkmire A. Am Asso Pharm Sci (AAPS) 2005:1-4
- Tanja Lipsanen, Osmo Antikainen, Heikki R¨aikk¨onen, Sari Airaksinen, Jouko Yliruusi. Int J Pharm 2007; 345:101–107.
- O'Callaghan D, Gaine SP. Bosentan: A novel agent for the treatment of pulmonary arterial hypertension. Int J Clin Pract 2004; 58:69-73.
- http://www.rxlist.com/tracleer-drug.htm
- https://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults.cfm
